Longchai Jiangxue Formula for the Treatment of Essential Thrombocythemia:A Randomized Controlled Study
Objective To evaluate the efficacy,anticoagulant role,and effect on aspirin resistance(AR)of Longchai Jiangxue Formula(LCJX)in treating essential thrombocythemia(ET).Methods Seventy-two patients with ET met the inclusion criteria at the Department of Hematology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,from October 2021 to December 2022,and were assigned to the control group and the observation group,with 36 cases in each group by using the method of randomized numerical table.The control group was given hydroxycarbamide≤1.0 g/d or pegylated interferon-α2a(PEG-INF α-2a)≤180 g/w or IFN-α-2b ≤ 9 million U/w,and aspirin ≤ 100 mg/d.The observation group added LCJX based on the control group treatment.Platelet counts,myeloproliferative neoplasm(MPN)-10 scores,disease progression and thrombosis or bleeding events were observed before and after treatment.Prothrombin time(PT),fibrinogen(FIB),D-Dimer(D-Di),activated partial thromboplastin time(APTT),platelet count(PLT),coagulation index(Cl),and maximal amplitude(MA)of thromboelastography(TEG)were used to assess the presence of hypercoagulable state in the patients as well as the effect of LCJX on coagulation function.Arachidonic acid(AA)-induced AA inhibition in TEG was applied to assess the occurrence of AR in patients with ET and the role of LCJX on AR.Results Among 72 patients,7 patients dropped off and 65 patients could be evaluated,32 in the observation group and 33 in the control group.Compared with the control group,the observation group showed a higher effective rate and lower PLT count and MPN-10 score(P＜0.05).No disease progression or thrombotic or bleeding events occurred in both groups during the treatment period.Of the two groups,29 patients(44.62％)were in a hypercoagulable state,14 cases in the control group and 15 cases in the observation group.Compared with the control group,the proportion of patients with hypercoagulable state was significantly lower in the observation group after treatment(P＜0.05).The incidence of AR in ET patients was 46.15％(30/65),16 patients in the control group and 14 in the observation group.Compared with the control group,the incidence of AA inhibition was significantly higher in the observation group(P＜0.05).No obvious adverse reactions occurred in the two groups.Conclusion LCJX can effectively reduce blood cell counts,improve symptoms,increase efficiency,and improve hypercoagulable state and AR in patients with ET.
国家科技期刊平台
NSTL
万方数据
